Evercore ISI analyst Vijay Kumar raised the firm’s price target on Exact Sciences (EXAS) to $70 from $60 and keeps an Outperform rating on the shares. In the firm’s 2025 outlook note for MedTech, Life ...
) has been revised to $84.57 / share. This is an increase of 18.76% from the prior estimate of $71.21 dated November 7, 2025. The price target is an average of many targets provided by analysts. The ...
BofA lowered the firm’s price target on Exact Sciences (EXAS) to $72 from $75 and keeps a Buy rating on the shares. The Life Sciences Tools sector underperformed again in FY24 as Pharma and Biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results